REVIEW OF DECISIONS

BOARD MEETING
24-25 June 2020, Virtual Meeting
Decision 1: Consent Agenda: Board and Committee nominations (1/4)

The Gavi Alliance Board:

a) **Approved** the exceptional extension of **Stephen Zinser** as:
   - Unaffiliated Board member effective 1 July 2020 and until 30 June 2021; and
   - Chair of the Investment Committee effective 1 July 2020 and until 30 June 2021.
b) **Approved** the exceptional extension of **David Sidwell** as:

- Unaffiliated Board member effective 1 January 2021 and until 31 December 2021;
- Chair of the Audit and Finance Committee effective 1 January 2021 and until 31 December 2021;
- Member of the Market-Sensitive Decisions Committee effective 1 January 2021 and until 31 December 2021; and
- Member of the Investment Committee effective 1 January 2021 and until 31 December 2021.
Decision 1: Consent Agenda: Board and Committee nominations (3/4)

c) **Appointed** the following Board Member:
   • **Mahima Datla** as Board Member representing the vaccine industry developing countries in the seat currently held by Sai Prasad effective 1 July 2020 and until 30 June 2023.

d) **Appointed** the following Alternate Board Member:
   • **Carmen Coles Tull** as Alternate Board Member representing the United States on the donor constituency anchored by the United States in the seat currently held by Irene Koek of the United States, effective immediately and until 31 December 2021.

e) **Appointed** the following to the Market-Sensitive Decisions Committee:
   • **Carmen Coles Tull** (Alternate Board Member), effective immediately and until 31 December 2021.
f) **Appointed** the following to the Audit and Finance Committee:

- **Carmen Coles Tull** (Alternate Board Member), effective immediately and until 31 December 2021.
- **Gianmarco Cocozza** (Committee Delegate), effective immediately and until 31 December 2021.

g) **Appointed** the following to the Programme and Policy Committee:

- **Sai Prasad** (Committee Delegate), effective 1 July 2020 and until 31 December 2021.
Decision 2: Consent Agenda: Independent Review Committee appointments

The Gavi Alliance Board:

**Ratified** the emergency exceptional extensions of the terms of Philippe Jaillard and Mario Stassen as members of the Independent Review Committee until 31 March 2021.
Decision 3: Consent Agenda: Appointment of Secretary

The Gavi Alliance Board:

**Appointed** Brenda Killen as Secretary with individual signatory authority effective 1 July 2020 and until her successor is appointed and qualified.
Decision 4: Consent Agenda: Revision of Statutes and Introduction of Operating Procedures

The Gavi Alliance Board:

a) **Approved** the amended Gavi Alliance Statutes attached as Annex A to Doc 01g;

b) **Agreed** to replace the Gavi Alliance By-laws with Board and Board Committee Operating Procedures; and

c) **Approved** the Board and Board Committee Operating Procedures attached as Annex B to Doc 01g.
Decision 5: Consent Agenda: Guiding Principles on Gender for Board and Committee nominations

The Gavi Alliance Board:

Approved the Guiding Principles on Gender for Board and Committee Nominations as set out in Annex A to Doc 01f, effective 1 July 2020.
Decision 6: Consent Agenda: Audit & Investigations Terms of Reference

The Gavi Alliance Board:

Approved a revised version of the Audit & Investigations Terms of Reference to incorporate certain changes resulting from observations made in the recently conducted External Quality Assessment attached as Annex B to Doc 01h.
Decision 7: Consent Agenda: UNICEF Fees

The Gavi Alliance Board:

a) **Approved**, within the overall Partners’ Engagement Framework:

i. An increase of US$ 2 million to the already Board-approved 2020 UNICEF Supply Division fees for the procurement of vaccine and related devices in 2020;

ii. A budget of US$ 21.4 million for UNICEF Supply Division fees for the procurement of vaccines, related devices and yellow fever surveillance and diagnostics equipment in 2021;

iii. A budget of US$ 4.3 million for UNICEF Supply Division fees for the procurement of cold chain equipment for 2021.

b) **Noted** that the Audit and Finance Committee reviewed the financial implications of the recommendations as set out in Figure 1 in Doc 03a to the 6 May 2020 meeting of the Audit and Finance Committee and concluded that these could be approved by the Board in accordance with the Programme Funding Policy.
Decision 8: Consent Agenda: Whistleblowing Policy

The Gavi Alliance Board:

Approved the revised and updated Whistleblowing Policy attached as Annex B to Doc 01f to be implement with effect from 1 July 2020.
Decision 9: COVID-19: Gavi’s Immediate and Interim Response

The Gavi Alliance Board recalling Decision 13 of 26-27 June 2019, and noting that any potential engagement with former and never Gavi-eligible countries should account for no more than 3% of Gavi planned expenditure in the 2021-2025 period:

a) **Approved** targeted support (excluding vaccine financing) to former Gavi-eligible countries to strengthen political will and to address an identified risk of reduction in coverage rates of vaccines introduced with Gavi support in that country, noting that the financial implications are expected to be up to US$ 20 million through 31 December 2020, to be funded through the flexibilities granted to the Gavi CEO by the Board in May 2020 to respond to the COVID-19 pandemic; and

b) **Requested** that the proposed approaches set out in Annex E to Doc 03 to engage with former and never Gavi-eligible countries be brought back to the PPC and the Board for consideration by no later than 31 December 2020.
Decision 10: COVID-19: Gavi’s Immediate and Interim Response (1/2)

The Gavi Alliance Board:

**Granted** the Secretariat the authority to implement the following policy shifts from 1 July 2020 within the existing policy framework, noting that these shifts were approved by the Board in December 2019 for incorporation into Gavi’s new funding policies:

a) Removing the programme filter requiring 70% or higher coverage of the 3rd dose of DTP-containing vaccine for a country to access new support for select vaccines (as set out in the Eligibility & Transition Policy);

b) Removing the cap of US$ 100 million over five years currently applied to total country HSS ceilings, but retaining the floor of US$ 3 million;
Decision 10: COVID-19: Gavi’s Immediate and Interim Response (2/2)

c) Integrating support for CCEOP into HSS support; and

d) Discontinuing the mechanism of awarding Performance Payments (as set out in the HSIS Support Framework).
Decision 11: COVID-19: Vaccine Development, Access and Delivery (1/2)

The Gavi Alliance Board:

a) With respect to the COVAX Facility:

i. **Noted** that the COVAX Facility is proposed as a time-limited global, coordinated mechanism designed to ensure rapid and equitable access to a safe and efficacious COVID-19 vaccine to as broad a global population as possible and that without such a mechanism, manufacturers may not expand production capacity to adequately address the global pandemic, leaving behind vulnerable populations across the globe and in particular those in the lower income countries served by Gavi;

ii. **Noted** that the Gavi Secretariat is acting as the administrator for the COVAX Facility to support its design and operationalisation and that the Secretariat will develop, for the Gavi Board’s consideration, a more detailed description of Gavi’s role in coordinating and operationalising the activities including how the Secretariat assumes liabilities on behalf of the COVAX Facility, as well as a tailored governance mechanism for the COVAX Facility;
Decision 11: COVID-19: Vaccine Development, Access and Delivery (2/2)

b) **Confirmed** Gavi’s role in supporting cold chain support for COVID-19 vaccines, diagnostics and treatments in 78 low and lower middle income countries and 12 IDA-eligible small economies, as agreed by the members of the ACT Accelerator, contingent on approval by the Board of a refined proposal to be developed by the Secretariat as described in Section 7 to Doc 05; and

c) **Provided** guidance on the proposal to consider support to countries on cold chain needs across PHC commodities and to further explore the use of CCEOP as a platform for health facility solarisation as part of a co-investment model with other donors.
Decision 12: Review of the Gavi Gender Policy

The Gavi Alliance Board:

**Approved** the revised Gavi Alliance Gender Policy attached as Annex B to Doc 07.
Thank you